Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.35 USD | -1.40% |
|
+0.32% | +92.72% |
Jun. 03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
Jun. 03 | Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program | CI |
Evolution of the average Target Price on Neurogene Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
![Consensus](/images/consensus_flch.gif)
Consensus detail
Consensus revision (last 18 months)
Analysts covering Neurogene Inc.
Leerink Partners | |
William Blair & Co. | |
HC Wainwright | |
Stifel Nicolaus | |
Mizuho Securities | |
Guggenheim | |
Canaccord Genuity | |
BofA Securities | |
Piper Sandler |
EPS Revisions
- Stock Market
- Equities
- NGNE Stock
- Consensus Neurogene Inc.